Alaunos Therapeutics, Inc.TCRTEarnings & Financial Report
Nasdaq
TCRT Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-1.2M
Net Profit
$-1.2M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.55
Alaunos Therapeutics, Inc. Q3 2025 Financial Summary
Alaunos Therapeutics, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-1.2M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-1.2M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Alaunos Therapeutics, Inc. Annual Revenue by Year
Alaunos Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $10.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $10.0K |
| 2023 | $5.0K |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1000 | $1000 | $4000 | $0 | $5000 | $2000 | $0 | $0 |
| YoY Growth | N/A | N/A | 0.0% | N/A | 400.0% | 100.0% | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $8.3M | $6.0M | $4.7M | $3.5M | $2.8M | $2.1M | $4.7M | $3.7M |
| Liabilities | $2.0M | $1.2M | $907000 | $826000 | $692000 | $1.1M | $1.1M | $921000 |
| Equity | $6.3M | $4.8M | $3.8M | $2.7M | $2.1M | $1.1M | $3.7M | $2.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.4M | $-1.9M | $-1.7M | $-781000 | $-592000 | $-772000 | $-701000 | $-844000 |